Guardant Health
Guardant Health provides blood-based liquid biopsy tests that enable early cancer detection, targeted therapy selection, and recurrence monitoring through analysis of circulating tumor DNA. The company's commercially available tests have been used by over 12,000 doctors in more than 1,000,000 procedures. Its product portfolio includes the Shield™ colorectal cancer screening test, the Guardant Complete® portfolio for advanced cancer genomic profiling, and Guardant Reveal® for minimal residual disease detection.
- Healthcare Technology
- Biotechnology
- Artificial Intelligence
- Data & Analytics
Funding
Raised to date
$557MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$390M across 2 disclosed rounds
+2$360M · Series E
Announced May 2017 · from article date
Disclosed cumulative: $390M
Reported total $557M
Incomplete round history. $167M of the $557M reported total isn’t matched to a known round.
Founders
Product
Problem
Traditional cancer detection and treatment selection methods often involve invasive procedures and can be time-consuming, potentially delaying critical interventions. Furthermore, existing screening options for certain cancers face challenges with patient adherence due to inconvenience or discomfort. This can lead to delayed diagnoses and suboptimal treatment outcomes.
Solution
Guardant Health offers a suite of advanced blood-based tests designed to provide comprehensive insights across the cancer care continuum. Leveraging liquid biopsy technology, their platform enables early cancer detection, aids in the selection of targeted therapies for advanced disease, and monitors for minimal residual disease (MRD) to predict recurrence. By analyzing circulating tumor DNA (ctDNA) and utilizing proprietary epigenomic and genomic profiling, Guardant Health aims to improve clinical decision-making and patient outcomes. Their approach seeks to overcome the limitations of traditional methods by offering less invasive, more accessible diagnostic tools.
Target Audience
Guardant Health serves patients, healthcare providers (oncologists, pathologists, primary care physicians), and biopharmaceutical companies involved in cancer research and treatment.
Features
- **Shield™ Blood Test:** A blood-based screening test for colorectal cancer that analyzes genomic alterations, methylation patterns, and fragmentomic signals to detect early signs of the disease in asymptomatic individuals.
- **Guardant Complete® Portfolio:** A comprehensive genomic profiling solution for advanced cancer, enabling the identification of actionable biomarkers to guide targeted therapy selection, including HER2 mutation status assessment.
- **Guardant Infinity™ Platform:** A proprietary, non-destructive DNA methylation technology that enhances molecule recovery for increased sensitivity in ctDNA detection, supporting multiomic insights that combine genomic, epigenomic, and RNA-based fusion data.
- **Guardant Reveal®:** A blood test designed for early-stage cancer patients to detect and quantify minimal residual disease (MRD) using methylation-based ctDNA analysis, aiding in recurrence prediction and adjuvant therapy decisions.
- **Guardant 360 Response™:** A test that monitors a patient's response to treatment, allowing for dynamic adjustments to therapy based on evolving molecular profiles.
- **BioPharma Solutions:** Services tailored for pharmaceutical partners, providing genomic and epigenomic profiling for translational research and clinical trial support.
- **AI-driven Data Analytics:** Utilization of real-world data and artificial intelligence to derive deeper insights from genomic and epigenomic analyses.